MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.26510

Медицинская библиотека · American journal of hematology · 2022

Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

Pommert Lauren, Schafer Eric S, Malvar Jemily, Gossai Nathan, Florendo Ellynore, Pulakanti Kirthi, Heimbruch Katelyn, Stelloh Cary, Chi Yueh-Yun, Sposto Richard, Rao Sridhar, Huynh Van Thu, Brown Patrick, Chang Bill H, Colace Susan I, Hermiston Michelle L, Heym Kenneth, Hutchinson Raymond J, Kaplan Joel A, Mody Rajen, O'Brien Tracey A, Place Andrew E, Shaw Peter H, Ziegler David S, Wayne Alan, Bhojwani Deepa, Burke Michael J

Клиническое исследование I фазыСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Survival outcomes for relapsed/refractory pediatric acute myeloid leukemia (R/R AML) remain dismal. Epigenetic changes can result in gene expression alterations which are thought to contribute to both leukemogenesis and chemotherapy resistance. We report results from a phase I trial with a dose expansion cohort investigating decitabine and vorinostat in combination with fludarabine, cytarabine, and G-CSF (FLAG) in pediatric patients with R/R AML [NCT02412475]. Thirty-seven patients enrolled with a median age at enrollment of 8.4 (range, 1-20) years. There were no dose limiting toxicities among the enrolled patients, including two patients with Down syndrome. The recommended phase 2 dose of decitabine in combination with vorinostat and FLAG was 10 mg/m2 . The expanded cohort design allowed for an efficacy evaluation and the overall response rate among 35 evaluable patients was 54% (16 complete response (CR) and 3 complete response with incomplete hematologic recovery (CRi)). Ninety percent of responders achieved minimal residual disease (MRD) negativity (<0.1%) by centralized flow cytometry and 84% (n = 16) successfully proceeded to hematopoietic stem cell transplant. Two-year overall survival was 75.6% [95%CI: 47.3%, 90.1%] for MRD-negative patients vs. 17.9% [95%CI: 4.4%, 38.8%] for those with residual disease (p < .001). Twelve subjects (34%) had known epigenetic alterations with 8 (67%) achieving a CR, 7 (88%) of whom were MRD negative. Correlative pharmacodynamics demonstrated the biologic activity of decitabine and vorinostat and identified specific gene enrichment signatures in nonresponding patients. Overall, this therapy was well-tolerated, biologically active, and effective in pediatric patients with R/R AML, particularly those with epigenetic alterations.

Для цитирования: Pommert Lauren, Schafer Eric S, Malvar Jemily, Gossai Nathan, Florendo Ellynore, Pulakanti Kirthi, Heimbruch Katelyn, Stelloh Cary, Chi Yueh-Yun, Sposto Richard, Rao Sridhar, Huynh Van Thu, Brown Patrick, Chang Bill H, Colace Susan I, Hermiston Michelle L, Heym Kenneth, Hutchinson Raymond J, Kaplan Joel A, Mody Rajen, O'Brien Tracey A, Place Andrew E, Shaw Peter H, Ziegler David S, Wayne Alan, Bhojwani Deepa, Burke Michael J. Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.. American journal of hematology. 2022. DOI: 10.1002/ajh.26510.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.